39 results about "Succinylation" patented technology

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K17 site succinylation modification and application. Experiments show that the 17-site lysine of the PGK1 protein has succinylation modification (PGK1 K17su), and the existence of the modification is confirmed through a specific succinylation modified antibody for the first time. Further, it is found that PGK1 K17su can weaken lung cancer cell oxidative phosphorylation and promote glycolysis metabolism by inhibiting lung cancer cell mitochondrial generation, and functional experiments prove that PGK1 K17 succinylation modification promotes proliferation and migration of lung cancer cells.

This invention belongs to the field of biomedicine, specifically relating to a therapeutic target for pancreatic cancer targeting the ECHS1 K115 site and its application. Through experiments, this invention discovered that the level of lysine succinylation modification at position 115 of the ECHS1 protein (ECHS1 K115su) is significantly decreased in pancreatic cancer tumors, and for the first time, the presence of this modification was confirmed using a specific succinylation modification antibody. Further findings revealed that K115 succinylation modification can mediate the conversion efficiency of ECHS1 protein to its substrates, thereby inhibiting fatty acid β-oxidation metabolism in pancreatic cancer cells. In vitro and in vivo functional experiments confirmed that ECHS1 K115 succinylation modification inhibits the proliferation of pancreatic cancer tumor cells and tumor volume growth.

The invention discloses a breast cancer cell succinylation monitoring method and system, and relates to the technical field of breast cancer cell succinylation monitoring, and the method comprises the following steps: S1, obtaining key metabolite concentration data of a breast cancer sample; s2, performing time sequence metabolic flux value analysis on the key metabolite concentration data to obtain a time sequence metabolic flux value, and performing feature extraction on the time sequence metabolic flux value to generate a metabolic flux distribution vector; s3, calculating succinylation level data based on the metabolic flux distribution vector; s4, quantitatively analyzing the fluctuation stability of the metabolic flux distribution, and generating fluctuation result data; s5, performing nonlinear coupling on the succinylation level data and the fluctuation result data to output comprehensive succinylation change information; s6, performing risk increase early warning prompt according to the comprehensive succinylation change information; the limitation problem existing in the current breast cancer cell succinylation monitoring process is solved, and the reliability and authenticity of the monitoring result are guaranteed.

The invention relates to the technical field of biological medicine, in particular to a specific antibody for detecting or targeting ALDOA-K13 succinylation modification and application of the specific antibody. The specific antibody for detecting or targeting ALDOA-K13 succinylation modification can be specifically combined with a succinylation modification site of 13th lysine of human ALDOA protein, and is not combined with ALDOA of an unmodified type or other modified types. The invention provides a specific antibody for detecting or targeting ALDOA-K13 succinylation modification for the first time, and fills the blank of existing detection tools. The antibody not only has high specificity and sensitivity, but also can be used for developing a novel tumor diagnosis and prognosis detection method.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K6 site succinylation modification and application. Experiments show that the 6th lysine of the PGK1 protein has succinylation modification (PGK1 K6su), and the existence of the succinylation modification at the 6th lysine is confirmed through immunoprecipitation experiments; cell function experiments prove that the PGK1 K6su enhances lung cancer cell migration and multiplication capacity and promotes lung cancer progression. A small molecule compound diammonium glycyrrhizinate aiming at the PGK1 K6 site is further obtained through computer-assisted screening, and subsequent experiments find that the compound can inhibit proliferation and migration of lung cancer cells by reducing the succinylation modification level of the lung cancer cells PGK1 K6.

The invention relates to the technical field of food, in particular to a method for preparing gel based on succinylation modified rice protein alkali heat induction. The preparation method comprises the following steps: firstly, acylating rice protein by adopting succinic anhydride to prepare rice protein with different acylation degrees; the influence of different alkaline solutions and alkaline environments with different pH values on the performance of inducing the rice protein to prepare the gel is further investigated. Compared with a traditional alkali heat induction process, the brand new rice protein gel preparation process provided by the invention is milder and safer. The application range of the rice protein in the food industry is expanded, and meanwhile, an important foundation is laid for developing safe, nutritional and palatable foods easy to swallow.

The invention discloses a method for preparing easy-to-eat food by regulating the electrostatic interaction of protein and a product, and the method comprises the following steps: adding 5-10% of charge modified egg white protein (phosphorylation and succinylation) into a black rice paste matrix, and carrying out thermal induction to form electrostatic cross-linked gel. According to the present invention, the limitation that the traditional thermally induced gel depends on disulfide bonds is broken through, the ionic bonds and the disulfide bonds cooperate to form the dynamic adjustable network, the IDDSI 5-level texture precise control is achieved, and the black rice anthocyanin processing retention rate is increased by 36.4%; the prepared product is suitable for patients with dysphagia such as stroke and senile dementia, and has high safety and nutritional functions.

The present technique pertains to a method of preparation of a succinylated collagen-fibrinogen hydrogel and a succinylated collagen-fibrinogen hydrogel prepared thereby. The method of preparation of a succinylated collagen-fibrinogen hydrogel according to the present technique can produce a collagen-based bio-substance in a simple process, wherein collagen can be prevented from being entangled and an improvement can be brought about in hydrophilicity, cell growth rate, cell compatibility, and cell diffusion capability, whereby the collagen-based bio-substance exhibits excellent biocompatibility in vivo.

The invention belongs to the technical field of nanoprobes, and relates to an iron-based polypeptide probe for regulating and controlling a mitochondrial function and application of the iron-based polypeptide probe in tumor inhibition drugs. The invention discloses an iron-based polypeptide probe for regulating and controlling a mitochondrial function, the iron-based polypeptide probe for regulating and controlling the mitochondrial function comprises superparamagnetic nano iron oxide SPION and a polypeptide ligand modified on the surface of the superparamagnetic nano iron oxide SPION, and the polypeptide ligand is an N-terminal succinylated D-type neuropeptide Y series polypeptide ligand S-DNPY; the iron-based polypeptide probe for regulating and controlling the mitochondrial function competitively inhibits a mitochondrial succinylation behavior under the action of SIRT5 enzyme and NAD + coenzyme on mitochondria, in-situ self-assembly is performed after succinylation is performed, iron-based polypeptide probe aggregation is realized, a mitochondrial membrane is damaged, and the mitochondrial function is regulated and controlled. And abnormal oxidation is triggered, and cell apoptosis and autophagy clearance of damaged mitochondria are induced. The invention also discloses a medicine for inhibiting tumors, which comprises the iron-based polypeptide probe for regulating and controlling the mitochondrial function.

The invention discloses a preparation method of a heat-resistant alpha-amylase inhibitor, and belongs to the technical field of natural plant protein extraction technology modification. The heat-resistant alpha-amylase inhibitor is obtained through degreasing extraction, ammonium sulfate fractional precipitation and succinylation modification, the alpha-amylase inhibition activity of 57.24% + / -0.62% can be achieved after high-temperature heat treatment, the heat resistance is high, and the inhibition activity retention rate reaches 68.23% + / -0.45%. The content of alpha-helix in the secondary structure of the heat-resistant alpha-amylase inhibitor is 14.92%, which plays an important role in maintaining the stability of the protein structure at high temperature. The alpha-amylase inhibitor disclosed by the invention breaks through the limitation that a common protein alpha-amylase inhibitor in the market is inactivated at a high temperature, can tolerate high-temperature treatment of 100 DEG C, retains corresponding activity, fills the blank of the alpha-amylase inhibitor in the heat treatment food processing industry, provides a new solution for diabetes intervened diet, and has a wide application prospect. The market development potential is wide.

The invention relates to the technical field of animal feed preparation, in particular to animal feed rich in protein and a preparation method thereof. The animal feed provided by the invention is prepared by taking the chemically induced and intensively cultured microalgae as a protein source, modifying the protein source through succinylation and then synergistically compounding the modified protein source with a composite chelating agent. The content of microalgae protein in the feed prepared by the method reaches 20% or above of dry weight, the total protein content of the feed is greater than or equal to 28%, the protein digestion and absorption rate of animals is increased to 88% or above, and meanwhile, the animal immune function is effectively enhanced.

The application provides a high-temperature-resistant and gastric acid-resistant probiotic preparation and a preparation method thereof, and the preparation comprises a probiotic core layer and a shell layer covering the same, and the shell layer comprises succinyl-modified food leaf protein assisted by ultrasonic pretreatment, peach gum polysaccharide and soybean lecithin. The application constructs a single-layer protection system with excellent responsiveness by performing specific functional modification on the food leaf protein and synergizing the food leaf protein with the peach gum polysaccharide and the soybean lecithin. The preparation can significantly improve the survival rate of probiotics during processing, storage and simulated gastrointestinal digestion, and especially realizes excellent gastric acid resistance and intestinal targeting release performance, and the process is simple and suitable for embedding and protecting various probiotics.

The invention discloses a preparation method of an easy-to-swallow shiitake mushroom pork product, which comprises the following steps: pretreating shiitake mushrooms, carrying out multi-stage fermentation to obtain a high-flavor shiitake mushroom fermented product, pretreating pork to prepare meat paste, mixing the meat paste with the shiitake mushroom fermented product, folic acid-succinylated konjac glucomannan, soybean protein isolate and other raw materials, stirring, molding, cooking, refrigerating and packaging to obtain the easy-to-swallow shiitake mushroom pork product. According to the invention, shiitake mushrooms are subjected to multi-stage fermentation treatment to obtain a high-flavor fermented product, and folic acid and succinylated compound modified konjac glucomannan are adopted to improve the instant solubility and water wettability of the shiitake mushrooms; the modified konjac glucomannan and the soybean protein isolate in the easy-to-swallow mushroom product form a continuous gel network composite matrix which is soft, uniform and high in cohesion, so that the product is smooth in texture, high viscosity and cohesion are maintained under low shearing force of an oral cavity, the viscosity is reduced under high shearing force during swallowing, low swallowing resistance, high cohesion and difficulty in residue are realized, and the bucking risk is reduced. Meanwhile, the product is rich in flavor, fresh and fragrant, high in nutrition density and suitable for people with dysphagia to eat.

This invention relates to the field of biomedical technology, disclosing succinylated modified RAD51 protein, formulations for promoting RAD51 succinylation, and their applications. The method includes: seeding and culturing cells and transfecting them with a tagged RAD51 expression plasmid; adding sodium succinate and an HDAC11 inhibitor to the culture medium for continued culturing to allow intracellular modification accumulation; collecting the supernatant after cell lysis and incubating it with magnetic beads containing anti-tag antibodies under cold conditions; washing and eluting with an elution buffer containing the tagged peptide; performing immunoblotting analysis using antibodies that specifically recognize the modified site to obtain the succinylated modified RAD51 protein. This invention, by adding sodium succinate and an HDAC11 inhibitor, provides a substrate and blocks the demodification pathway. Combined with magnetic bead purification and competitive elution, it avoids disrupting the protein conformation, obtaining a protein that retains its native activity and has a high level of modification, providing a core component for screening targeted drugs.

The invention specifically discloses an acute myelogenous leukemia prognostic marker and application thereof, and relates to the technical field of biological medicines. The invention provides an application of a protein lysine succinylation modification level as an acute myelogenous leukemia diagnosis and / or prognosis marker, and clinical data, cell experiments and animal experiments prove that the protein lysine succinylation modification level is related to AML prognosis and is a supplement of an existing prognosis system. Ksuc can be detected through a multi-parameter flow type technology, the method is simple, convenient and rapid, the experimental period is only several hours, Ksuc can be obtained when conventional immune typing detection is carried out at the beginning of diseases, and the experimental period is shorter than that of existing prognosis factors adopting next-generation sequencing, traditional PCR and the like. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.

The invention discloses a preparation method and application of modified oat protein, and belongs to the technical field of food processing. According to the invention, the avenin is extracted by combined use of microwave treatment and high-pressure extraction, and the modified avenin is prepared by combined use of succinylation modification and ultrasonic treatment; the method mainly comprises the following steps: pretreatment, dissolution, microwave treatment, extraction, centrifugation, modification, purification, concentration, drying and crushing to finally obtain the modified oat protein. According to the method, the oat protein is extracted in a manner of combining microwave treatment and high-pressure extraction, so that the extraction efficiency and purity of the oat protein are improved; the avenin is modified by adopting a succinylation mode, so that the solubility of the avenin is improved; a manner of combining succinylation, PBS (Phosphate Buffer Solution) and ultrasonic treatment is adopted for modification, so that the modification efficiency is further improved; compared with conventional avenin, the modified avenin prepared by the method has better dispersity and solubility.

The present invention provides a mutant of soybean lipoxygenase LOX2 and its application in creating odorless soybeans. The mutant is based on the parent amino acid sequence of SEQ ID NO.1. By introducing succinylation modifications at lysine residues 257, 263, and 472, the catalytic efficiency of LOX2 is reduced, reducing the oxidation of polyunsaturated fatty acids and effectively creating odorless soybeans. Compared with the wild type, the catalytic efficiency is reduced by 15.62%, providing a new basis for application in the food industry. In addition, by achieving molecular-level transformation through grafting breeding technology, the present invention not only improves soybean quality but also significantly reduces production costs, which is of great significance for soybean variety improvement and oil quality improvement.

Protein polyurethane alloys including one or more succinylated proteins dissolved within one or more polyurethanes. The protein polyurethane alloys may have one or more mechanical properties that are superior to the polyurethane in the absence of protein. The protein polyurethane alloys may be incorporated into a layered material including one or more protein polyurethane alloy layers.

The present application belongs to the field of biological medicine, and particularly relates to a teriparatide oral preparation, a preparation method and application thereof. Specifically, the present application provides a teriparatide oral preparation, which comprises exosome-encapsulated teriparatide, wherein the surface of the exosome is grafted with succinylated epsilon-polylysine. The present application uses exosomes grafted with succinylated epsilon-polylysine to encapsulate and orally deliver teriparatide, and it is found that the exosomes can realize the release of teriparatide in the intestinal tract, and can also promote the intestinal wall permeability of teriparatide, thereby significantly improving the bioavailability of the oral teriparatide.

The application belongs to the field of drug delivery nanotechnology, and provides a method for preparing cubic lipid nanoparticles encapsulating small interfering ribonucleic acid and application thereof. The application adopts a trinity design of ion complex pre-assembly of succinylated glycerol monooleate and cationic lipids, space stabilization of poloxamer 407, and rapid particle formation by microfluidics, realizes stable construction of internal nanostructure of inverse bicontinuous cubic phase, encapsulation of small interfering ribonucleic acid in water channel network with high drug loading, long-term stability of colloids under physiological ion strength conditions, and excellent batch consistency, solves the technical contradictions of existing lipid nanometer delivery systems, such as difficulty in giving consideration to low polydispersion and batch consistency, mutual restraint of cationic complex strength and colloidal stability, and difficulty in synergistic optimization of high drug loading and stability of cubic phase structure under high solid content microfluidic conditions, and has wide application value in gene therapy and nucleic acid drug delivery.

The invention belongs to the technical field of magnetic nanoparticles, and relates to polypeptide-modified magnetic nanoparticles for MRI (Magnetic Resonance Imaging) and application of the polypeptide-modified magnetic nanoparticles. The invention discloses a polypeptide modified magnetic nanoparticle for MRI (Magnetic Resonance Imaging) imaging, the polypeptide modified magnetic nanoparticle comprises superparamagnetic nano iron oxide SPION and a polypeptide ligand modified on the surface of the superparamagnetic nano iron oxide SPION, and the polypeptide ligand is N-terminal succinylated D-type neuropeptide Y series polypeptide ligand S-DNPY; the magnetic nanoparticles S-DNPY-SPION modified by the succinylated polypeptide are imaged in an MRI (Magnetic Resonance Imaging) signal T1; the magnetic nanoparticles modified by the succinylated polypeptide are subjected to succinylation under the action of SIRT5 enzyme and NAD < + > coenzyme and then subjected to in-situ self-assembly to obtain a magnetic nanoparticle assembly modified by the succinylated polypeptide, and the magnetic nanoparticle assembly modified by the succinylated polypeptide is imaged under an MRI signal T2.

This invention belongs to the field of biomedical material preparation technology, specifically disclosing a method for moist heat sterilization of recombinant collagen fillers. The method includes: preparing a protective solution from modified trehalose and proline, then mixing it with homogenized recombinant collagen hydrogel, followed by staged temperature-controlled moist heat sterilization. This invention modifies trehalose by succinylation, introducing carboxyl groups onto the trehalose molecule, enabling electrostatic interactions with cationic groups on the surface of collagen molecules. During moist heat sterilization, free proline guides the heat-denatured collagen to refold into its natural triple helix structure. The preheating stage allows the collagen to gradually adapt to the thermal environment, avoiding conformational shock damage caused by sudden temperature increases, effectively shortening the high-temperature sterilization time, and significantly reducing the cumulative heat effect on molecular structure. This method is simple to operate, requires no special equipment, and has good prospects for industrial application.

The invention provides an application of a targeted succinyl-coenzyme A synthetase (SUCLG1) in treatment of mitochondrial generation dependent tumors. Specifically, the invention provides an application of an inhibitor targeting SUCLG1, and the inhibitor is used for preparing drugs for promoting succinylation modification of mitochondrial RNA polymerase (POLRMT) and inhibiting the activity of POLRMT so as to reduce mitochondrial biogenesis. And / or a composition or formulation for treating or preventing a mitochondrial biogenesis dependent tumor or cancer. The invention discloses an internal mechanism of the SUCLG1 for regulating mitochondrial biogenesis for the first time, and in-vivo and in-vitro experiments prove that the target inhibition of the SUCLG1 has a remarkable inhibition effect on the progress of mitochondrial generation dependent tumors, and a new target is provided for tumor treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted CANX and SIRT7 combined polypeptide inhibitor and application thereof in lung adenocarcinoma radiation resistance treatment. The polypeptide has a sequence TKPPSRRPKL (SEQ ID NO: 1), and can be competitively combined with CANX protein and block succinylation modification of SIRT7 on the CANX protein, so that the localization and function of CANX in MAM are recovered, mitochondrial metabolism reprogramming is reversed, and the radiosensitivity of lung adenocarcinoma cells is enhanced. Experiments show that the polypeptide can significantly inhibit the combination of CANX and SIRT7 in vitro and improve the radiosensitivity of radiation-resistant lung adenocarcinoma cells. The invention provides a new targeting strategy and drug candidate for treatment of lung adenocarcinoma radiation resistance.

The invention discloses an esophageal cancer immune data prediction device and equipment based on a tumor marker and a storage medium, and relates to the technical field of electric digital data processing, the device constructs a more comprehensive tumor microenvironment evaluation system through ctDNA 5hmC epigenome sequencing and tumor tissue succinylation modification level analysis, and the tumor microenvironment evaluation system is used for evaluating the esophageal cancer immune data. The problem that a traditional biomarker (such as PD-L1 expression and tumor mutation load) is poor in prediction effect is solved; secondly, dynamic ctDNA data are processed through a time sequence channel and succinylation scores are processed through a static channel through a double-channel LSTM-Cox hybrid model, and advantage complementation of the two kinds of data is achieved; and finally, quantizing complex immune data into three intuitive good / general / poor scoring intervals to provide a clear treatment decision basis for clinicians. The scoring system can obviously reduce the invalid treatment rate.

The present application belongs to the technical field of modified yeast protein, and particularly relates to a double modified yeast protein purification product, a heat-induced gel and preparation and application thereof. The solubility of the double modified yeast protein purification product is greater than 15.00%, the turbidity is less than 1.70, the particle size is less than 1500.00 nm, the Zeta potential is less than -47.00 mV, and the succinylated degree is greater than 20.00%. The double modified yeast protein purification product is obtained by mixing yeast protein powder suspension with a pH of 7.0-11.0 and succinic anhydride at a dry matter mass ratio of 0.1:1-0.5:1, then performing succinylation reaction, ultrasonic treatment under a ultrasonic power of 200-600 W, and dialysis. The present application promotes specific conformational changes and interactions of modified yeast protein molecules in the double modified yeast protein purification product by controlled heat-induced technology, and a double modified yeast protein heat-induced gel product with good gel performance, transparency, water holding capacity and gel strength is prepared.

This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan–poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.

The invention relates to application of CSRP1 as a target spot in regulation and control of cancer-related fibroblasts and treatment of high-grade serous ovarian cancer, and belongs to the technical field of biological medicine. A large number of experiments prove that CSRP1 is expression down-regulation in an HGSOC sample; low expression of CSRP1 in CAF is closely related to poor prognosis of HGSOC patients, and CSRP1 expressed in CAF limits growth and metastasis of tumors by inhibiting activation of CAF. And the lysine 141 site (K141) is the most critical Ksucc site of the CSRP1 (CSRP1). The CPT1A reduces the expression level of the CSRP1 in the CAF by inducing the interaction between the succinylation modification of the K141 site of the CSRP1 and the ubiquitination modification of the K173 site of the CSRP1. Overexpression of the CSRP1 can change exosome protein components secreted by the CAF, so that communication between the exosome-mediated CAF in the HGSOC and tumor cells is influenced. The invention reveals the importance of Ksucc in the progress of HGSOC, and CSRP1 targeting CAF may have a therapeutic value.

The invention belongs to the field of biological medicine, and particularly relates to a pancreatic cancer treatment target aiming at an ECHS1 K115 site and application. Experiments show that the level of 115-site lysine succinylation modification (ECHS1 K115su) of ECHS1 protein is remarkably reduced in pancreatic cancer tumors, and existence of the modification is confirmed through a specific succinylation modified antibody for the first time. It is further found that K115 succinylation modification can mediate the conversion efficiency of ECHS1 protein to a substrate of the K115 succinylation modification so as to inhibit oxidative metabolism of pancreatic cancer cell fatty acid beta, and in-vivo and in-vitro functional experiments prove that ECHS1 K115 succinylation modification inhibits proliferation of pancreatic cancer tumor cells and tumor volume increase.